An FDA panel recommended against approving Forest Laboratories' hypertension drug Bystolic for treating heart failure, saying clinical data were not sufficient to prove the treatment's safety. Forest President and Chief Operating Officer Larry Olanoff said the company is disappointed but will confer with the agency on possibly adding a label that conveys information about the heart failure study.

Full Story:

Related Summaries